Found 582 Barrett's Esophagus trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Study Comparing the Effect of Drug Abelacimab Relative to Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Gastrointestinal (GI) / Genitourinary (GU) Cancer Associated VTE
This research study is being done to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking dalteparin. Your participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total …
ALAMO: AlloSure Lung Assessment and Metagenomics Outcomes study
The research study is being conducted to help clinicians monitor lung transplant patients to examine the risk for allograft rejection and/or infection. The registry will collect medical information and history related to your lung transplant care (medications, diagnoses, and other information in your medical record), storing that information in a …
I5T-MC-AACI Assessment of Safety Tolerability and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease Phase II
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
Study To Assess Efficacy Safety And Pharmacokinetics Of Iptacopan (LNP023) In Participants With Autoimmune Benign Hematological Disorders
The main purpose of this study is to evaluate the efficacy and safety of the investigational drug iptacopan (LNP023) in people with primary ITP or primary CAD. You will be in the study about 6 months with the opportunity to extend the total duration to about 31 months if you …
A Phase Ib Open-Label Multicenter Study To Investigate The Pharmacokinetics Safety And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis
Requesting a reliance agreement with an external IRB. Study to evaluate pharmacokinetics, safety/tolerability, and immunogenicicty of ocrelizumab admistered subcutaneously in patients with MS. Pre-treated patients will be randomized (1:1) to dose-escalated, subcutaneous or IV administration. Treatment naive patients receive dose-escalated, subcutaneous administration only. All participants may then enter a dose …
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single subretinal administration of RGX-314 (IRB #827859). Participants will be followed for up to 5 years post-RGX-314 …
HIS-BUNDLE CORRECTIVE PACING IN HEART FAILURE
The aim is to prospectively evaluate the efficacy and mechanism of benefit of HI-CRT vs. BIV CRT in patients with Right Bundle Brank Block (RBBB). Left Ventricular Ejection Fraction (LVEF) will be assess at 6 months following HIS CRT Vs. BIV CRT implant in Heart Failure patients with RBBB.
The COvid19 VaccinE Response in Rheumatology Patients (COVER)
This study is designed to evaluate the efficacy and safety of SARS-CoV-2 vaccines in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. Adults with psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) will be enrolled. The study involves data and …
Pragmatic Phase Iii Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
This is a pragmatic randomized clinical trial in which patients with locally advanced breast cancer will be randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life (HRQOL), and cancer control outcomes. We hypothesize that proton therapy, as part of multi-modality …
KCP-330-020
The purpose of this study is to see if the investigational drug, selinexor, has any effects in eligible participants with advanced unresectable dedifferentiated liposarcoma (DDLS). Selinexor will be given at a fixed oral dose of 60mg or placebo twice weekly on Days 1 and 3 during Weeks 1-6 of each …
Please choose between Voice or SMS based delivery of verification code
or